134 related articles for article (PubMed ID: 11411657)
1. Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients.
Wu SC; Lin SL; Jeng FR
Scand J Urol Nephrol; 2001 Apr; 35(2):136-40. PubMed ID: 11411657
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-term erythropoietin therapy on the hypothalamo-pituitary-testicular axis in male CAPD patients.
Tokgöz B; Utaş C; Dogukan A; Güven M; Taşkapan H; Oymak O; Keleştimur F
Perit Dial Int; 2001; 21(5):448-54. PubMed ID: 11757827
[TBL] [Abstract][Full Text] [Related]
3. Alterations in sex hormones and sexual function of patients with renal failure treated with recombinant human erythropoietin.
Suzuki H; Murakami M; Ichihara A; Saruta T
Nihon Jinzo Gakkai Shi; 1992 Jan; 34(1):79-84. PubMed ID: 1593800
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietin and sexual dysfunction.
Lawrence IG; Price DE; Howlett TA; Harris KP; Feehally J; Walls J
Nephrol Dial Transplant; 1997 Apr; 12(4):741-7. PubMed ID: 9141005
[TBL] [Abstract][Full Text] [Related]
5. [Influence of long-term erythropoietin (rHuEPO) therapy on the function of the pituitary-gonadal axis in hemodialyzed male patients with end stage renal failure].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Pol Arch Med Wewn; 1995 Aug; 94(2):144-52. PubMed ID: 8596749
[TBL] [Abstract][Full Text] [Related]
6. Effect of recombinant human erythropoietin (r-HuEPO) therapy on plasma FT3, FT4, TSH, FSH, LH, free testosterone and prolactin levels in hemodialysis patients.
Yeksan M; Tamer N; Cirit M; Türk S; Akhan G; Akkus I; Erkul I
Int J Artif Organs; 1992 Oct; 15(10):585-9. PubMed ID: 1428205
[TBL] [Abstract][Full Text] [Related]
7. Improved sexual function during recombinant human erythropoietin therapy.
Bommer J; Kugel M; Schwöbel B; Ritz E; Barth HP; Seelig R
Nephrol Dial Transplant; 1990; 5(3):204-7. PubMed ID: 2113648
[TBL] [Abstract][Full Text] [Related]
8. Effects of erythropoietin on gonadotropin responses to gonadotropin-releasing hormone in uremic patients.
Díez JJ; Iglesias P; Bajo MA; de Alvaro F; Selgas R
Nephron; 1997; 77(2):169-75. PubMed ID: 9346383
[TBL] [Abstract][Full Text] [Related]
9. Influence of erythropoietin on paradoxical responses of growth hormone to thyrotropin-releasing hormone in uremic patients.
Díez JJ; Iglesias PL; Sastre J; Gómez-Pan A; Selgas R; Martínez-Ara J; Miguel JL; Méndez J
Kidney Int; 1994 Nov; 46(5):1387-91. PubMed ID: 7853798
[TBL] [Abstract][Full Text] [Related]
10. Prolactin, gonadotropins, testosterone, and estrogens in uremic men undergoing periodic hemodialysis.
Mastrogiacomo I; Feghali V; De Besi L; Serafini E; Gasparotto L
Arch Androl; 1982 Dec; 9(4):279-82. PubMed ID: 7165408
[No Abstract] [Full Text] [Related]
11. Influence of long term erythropoietin therapy on the hypothalamic-pituitary-thyroid axis in patients undergoing capd.
Tokgöz B; Utaş C; Doğukan A; Oymak O; Keleştimur F
Ren Fail; 2002 May; 24(3):315-23. PubMed ID: 12166698
[TBL] [Abstract][Full Text] [Related]
12. [Effect of low-dose recombinant humane erythropoietin therapy on the quality of life in patients with anemia in the course of end-stage renal failure treated with dialysis].
Matuszkiewicz-Rowińska J; Marusza W; Andrzejewski A; Goliat E; Pacocha E; Switalski M; Zawadzka M; Ostrowski K
Pol Arch Med Wewn; 1996 Aug; 96(2):143-52. PubMed ID: 9122002
[TBL] [Abstract][Full Text] [Related]
13. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
14. Targeting higher ferritin concentrations with intravenous iron dextran lowers erythropoietin requirement in hemodialysis patients.
DeVita MV; Frumkin D; Mittal S; Kamran A; Fishbane S; Michelis MF
Clin Nephrol; 2003 Nov; 60(5):335-40. PubMed ID: 14640239
[TBL] [Abstract][Full Text] [Related]
15. Improvement of thyroid hormone profile and thyrotrophin (TSH) surge alterations in hemodialysis patients on erythropoietin treatment.
Utas C; Taskapan H; Oymak O; Akpolat T; Arinsoy T; Kelestimur F
Clin Nephrol; 2001 Jun; 55(6):471-6. PubMed ID: 11434359
[TBL] [Abstract][Full Text] [Related]
16. Influence of relative hypoparathyroidism on the responsiveness to recombinant human erythropoietin in hemodialysis patients.
Hsu SP; Peng YS; Pai MF; Hung KY; Tsai TJ
Blood Purif; 2003; 21(3):220-4. PubMed ID: 12784047
[TBL] [Abstract][Full Text] [Related]
17. Is it time for a paradigm shift? Is erythropoietin deficiency still the main cause of renal anaemia?
Eschbach JW; Varma A; Stivelman JC
Nephrol Dial Transplant; 2002; 17 Suppl 5():2-7. PubMed ID: 12091599
[TBL] [Abstract][Full Text] [Related]
18. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
19. [Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo C; Soto C; Neira F; López MD; Jiménez S; Albalate M; de Oña R; Llamas P; Deudero JJ
Nefrologia; 2004; 24(4):351-6. PubMed ID: 15455495
[TBL] [Abstract][Full Text] [Related]
20. [Improvement of sexual function in hemodialyzed male patients with chronic renal failure treated with erythropoietin (rHuEPO)].
Trembecki J; Kokot F; Wiecek A; Marcinkowski W; Rudka R
Przegl Lek; 1995; 52(9):462-6. PubMed ID: 8834648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
